罗氟司特用药注意事项

Roflumilast is mainly used for chronic obstructive pulmonary disease (COPD). Roflumilast is a long-acting inhibitor of selective phosphodiesterase type 4 (PDE-4) and has anti-inflammatory effects. Phosphodiesterases are a family of enzymes including at least 11 subtypes of enzymes that catalyze the decomposition of the messenger molecules cyclic adenosine monophosphate and/or cyclic guanosine monophosphate. Phosphodiesterase-4 is a major cyclic adenosine monophosphate metabolic enzyme in inflammatory and immune cells, and phosphodiesterase-4 inhibitors have broad anti-inflammatory activities including inhibiting the release of inflammatory mediators and inhibiting immune cell activation. In addition, phosphodiesterase-4 inhibitors have also been shown to have therapeutic effects in animal models of airway inflammation. In vivo, roflumilast has an effect on multiple aspects of the pathogenesis of chronic obstructive pulmonary disease (COPD), such as tobacco-induced pulmonary inflammatory response, respiratory ciliary dyskinesia, pulmonary fibrosis, emphysema, airway remodeling, oxidative stress response, pulmonary vascular remodeling and pulmonary hypertension.

Precautions when taking roflumilast:

Acute bronchospasm: Do not use to relieve acute bronchospasm.

Treatment with roflumilast may result in psychiatric events including suicidal behavior: Advise patients, their caregivers, and families to be alert to the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts or other mood changes, and to contact their healthcare provider if such changes occur. Carefully weigh the risks and benefits of treatment with roflumilast in patients with a history of depression and/or suicidal thoughts or behaviors.

Treatment with roflumilast may result in weight loss: monitor weight regularly. If unexplained or clinically significant weight loss occurs, evaluate weight loss and consider discontinuing roflumilast.

Drug Interactions While Treating with Roflumilast: It is not recommended to use with strong cytochrome P450 enzyme inducers (eg, rifampicin, phenobarbital, carbamazepine, phenytoin).

The above is the introduction about roflumilast. If patients have other questions about the drug (such as drug price, purchasing channels, etc.), they can consult the medical companion travel service.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: